Usefulness of the ID-Migraine Screening Tool for Diagnosing Migraines in Patients With Headache and Facial Pain: A Systematic Review and Meta-Analysis

Do Hyun Kim; David W. Jang; Se Hwan Hwang

doi:10.18787/jr.2025.00019

J Rhinol > Volume 33(1); 2026

Kim, Jang, and Hwang: Usefulness of the ID-Migraine Screening Tool for Diagnosing Migraines in Patients With Headache and Facial Pain: A Systematic Review and Meta-Analysis

Review

Journal of Rhinology 2026;33(1):1-10.

Published online: March 31, 2026

DOI: https://doi.org/10.18787/jr.2025.00019

Usefulness of the ID-Migraine Screening Tool for Diagnosing Migraines in Patients With Headache and Facial Pain: A Systematic Review and Meta-Analysis

Do Hyun Kim, MD, PhD¹

, David W. Jang, MD²

, Se Hwan Hwang, MD, PhD³

¹Department of Otolaryngology-Head and Neck Surgery, Seoul St. Mary’s Hospital, College of Medicine, The Catholic University of Korea, Seoul, Republic of Korea

²Department of Head and Neck Surgery & Communication Sciences, Duke University School of Medicine, Durham, NC, USA

³Department of Otolaryngology-Head and Neck Surgery, Bucheon St. Mary’s Hospital, College of Medicine, The Catholic University of Korea, Seoul, Republic of Korea

Address for correspondence: Se Hwan Hwang, MD, PhD, Department of Otolaryngology-Head and Neck Surgery, Bucheon St. Mary’s Hospital, College of Medicine, The Catholic University of Korea, 327 Sosa-ro, Bucheon 14647, Republic of Korea,
Tel: +82-32-340-7044, Fax: +82-32-340-2674, E-mail: yellobird@catholic.ac.kr

Received March 25, 2025 Revised April 30, 2025 Accepted May 1, 2025

This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (https://creativecommons.org/licenses/by-nc/4.0) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract

Background and Objectives

A substantial proportion of patients presenting with sinus headaches are ultimately diagnosed with migraines. The ID-Migraine tool has been developed to aid in identifying migraine patients in primary care settings. Therefore, we conducted a meta-analysis of validation studies evaluating the diagnostic accuracy of the ID-Migraine tool.

Methods

Data were extracted regarding true positives, false positives, true negatives, and false negatives, along with study characteristics. Methodological quality was assessed using the Quality Assessment of Diagnostic Accuracy Studies-2 (QUADAS-2) tool.

Results

In total, 30 studies involving 9,942 participants were included in the final analysis. The pooled diagnostic odds ratio for the ID-Migraine tool was 13.84. The area under the summary receiver operating characteristic curve was 0.846. The pooled sensitivity and specificity were 0.865 and 0.702, respectively, while the negative predictive value was 0.791 and the positive predictive value was 0.799.

Conclusion

The ID-Migraine screening tool is highly accurate and user-friendly for identifying migraines among patients presenting with sinus headaches. By employing this tool, unnecessary diagnostic tests or treatments can be minimized, and patients can be promptly referred to appropriate specialists.

KEY WORDS: Migraine disorders; Facial pain; Headache; Diagnosis; Meta-analysis

INTRODUCTION

Patients experiencing various facial or headache syndromes accompanied by rhinological symptoms—commonly termed “sinus headache”—frequently consult otolaryngologists, either through self-referral or referrals from other healthcare providers. However, many of these patients are ultimately diagnosed with migraines [1]. Otolaryngologists should be prepared to evaluate and manage these cases, particularly in determining whether facial pain originates from rhinogenic or migrainous causes [2,3]. Additionally, the global age-standardized prevalence of migraines increased by 1.7% between 1990 and 2019, with current prevalence estimates ranging from 8% to 22%. Approximately 1.1 billion people worldwide are estimated to suffer from migraines [4]. Given this significant prevalence, migraines are frequently encountered in clinical practice, making it critical for otolaryngologists to actively participate in managing patients presenting with migraines that include rhinologic symptoms.

The ID-Migraine screening tool was developed to simplify the identification of migraine patients in primary care environments [5]. This tool has been validated across various clinical contexts [6].

We hypothesize that this tool may serve as a practical and efficient initial screening instrument for distinguishing sinogenic headaches from migraines. Therefore, we conducted a meta-analysis of validation studies examining the ID-Migraine tool to assess its diagnostic accuracy specifically for patients with migraines.

METHODS

Study protocol and registration

This systematic review and meta-analysis were performed following the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines [7]. The study protocol was pre-registered on the Open Science Framework (https://osf.io/3gsy5/).

Literature search strategy

A comprehensive, systematic literature search was conducted in several electronic databases, including PubMed, Scopus, Embase, Web of Science, and the Cochrane Central Register of Controlled Trials, to identify relevant clinical studies published up to January 2025. The search strategy combined keywords and controlled vocabulary terms related to migraine diagnosis, including “migraine disorders,” “ID-Migraine,” “sensitivity and specificity,” as well as various forms of the terms “diagnose,” “diagnosis,” “diagnostic,” and “differential diagnosis.” A complete list of the specific search terms and queries is provided in Supplementary Table 1 (in the online-only Data Supplement).

To maximize comprehensiveness, the reference lists of all included studies were meticulously examined to identify additional relevant articles potentially missed in the initial search. Two reviewers (DHK and SHH) independently screened the titles, abstracts, and full texts of retrieved studies to exclude those not directly related to the use of the diagnostic tool for migraines. In cases of disagreement, discrepancies were resolved through discussion and consultation with a third reviewer (DWJ), ensuring accuracy and consistency in study selection.

Selection criteria

Studies meeting the following predefined eligibility criteria were included: 1) studies involving patients experiencing headache symptoms; 2) cohort studies or randomized controlled trials; 3) studies published in English; and 4) studies that directly compared the performance of the ID-Migraine tool against a confirmed migraine diagnosis established according to the International Classification of Headache Disorders (ICHD-II or III) criteria [8,9]. These criteria ensured that only relevant, high-quality studies were analyzed.

Studies were excluded if they were review articles, case reports, or commentaries; focused on headache types other than migraines, such as cluster headaches, tension-type headaches, or secondary headache disorders; or lacked sufficient data necessary for meaningful analysis. Additionally, studies with ambiguous diagnostic criteria or without clearly defined methods for confirming migraines were excluded.

A detailed overview of the study selection process, including the number of records screened, excluded, and included in the final analysis, is visually summarized in Fig. 1.

Data organization and risk of bias assessment

Data from selected studies were systematically extracted using a standardized data collection form to ensure accuracy and consistency [10,11]. The primary outcomes analyzed included the diagnostic odds ratio (DOR), summary receiver operating characteristic (sROC) curve, and the area under the curve (AUC). Together, these provided a comprehensive evaluation of the diagnostic performance of the ID-Migraine tool [5,12–40].

The DOR, a single indicator of test effectiveness, was calculated using the formula: (true positives [TPs]/false positives [FPs]) divided by (false negatives [FNs]/true negatives [TNs]). This metric quantifies the odds of a positive test result in migraine patients relative to the odds in individuals without migraines. Random-effects models were employed to compute DOR values with 95% confidence intervals (CIs), accounting for both within-study variability and heterogeneity between studies. DOR values theoretically range from 0 to infinity, with higher values indicating better diagnostic accuracy; a value of 1 indicates no discriminatory power.

The sROC curve was utilized to summarize the balance between sensitivity and specificity, providing a visual representation of the diagnostic accuracy. Curves positioned closer to the top-left corner of the ROC space indicate superior diagnostic performance, reflecting high sensitivity and specificity. To further quantify diagnostic accuracy, the AUC was calculated, with values ranging from 0 to 1. The AUC scores were interpreted as follows: ≥0.90 indicated excellent accuracy, 0.80–0.89 good accuracy, 0.70–0.79 fair accuracy, 0.60–0.69 poor diagnostic value, and <0.60 insufficient accuracy for clinical application [41].

In addition to these statistical analyses, data on the total number of patients in each study, along with TP, TN, FP, and FN values, were extracted to facilitate the calculation of AUC and DOR. Furthermore, the Quality Assessment of Diagnostic Accuracy Studies-2 (QUADAS-2) tool was employed to evaluate methodological quality and risk of bias in the included studies, ensuring a rigorous assessment of study reliability and potential limitations [42].

Statistical analysis and outcome measurements

The meta-analysis was performed using R statistical software (version 4.4.2; R Foundation for Statistical Computing), providing a robust and reproducible analytical approach. Statistical computations were conducted using specialized meta-analysis packages within R, enabling comprehensive evaluation of diagnostic performance across the studies.

To assess heterogeneity among studies, the Q statistic was applied, with a corresponding p-value to determine whether variability across studies was due to true differences in effect sizes or random sampling error. Additionally, the I² statistic was calculated to quantify the percentage of total variation attributable to heterogeneity rather than chance, with higher values indicating greater inconsistency between studies.

Subgroup analyses were performed to explore potential sources of heterogeneity, focusing particularly on variations across imaging modalities and other study characteristics potentially influencing diagnostic performance. These subgroup analyses assessed whether specific methodological factors contributed to variations in sensitivity and specificity estimates.

Forest plots were generated to visually represent key diagnostic parameters, including sensitivity, specificity, and the sROC curve. These graphical summaries aided interpretation of findings by displaying individual and pooled estimates of diagnostic performance, along with their respective confidence intervals.

To evaluate potential publication bias, Deeks’ funnel plot asymmetry test was utilized. This statistical method evaluates whether smaller studies with less favorable results are underrepresented, thus ensuring the reliability of synthesized findings. If significant asymmetry was detected in the funnel plot, additional sensitivity analyses were performed to explore its potential impact on overall conclusions.

RESULTS

Search and study selection

In total, 30 studies involving 9,942 participants were included in this analysis. The key characteristics of these studies are summarized in Table 1, and their bias assessments are provided in Supplementary Table 2 (in the online-only Data Supplement). The p-value obtained from Deeks’ funnel plot asymmetry test was 0.0835, indicating no significant evidence of publication bias (Fig. 2).

Diagnostic accuracy of different cutoff values in ID-Migraine

The pooled DOR for the ID-Migraine tool was 13.84 (95% CI, 10.21–18.76; I²=89.7%) (Fig. 3). The pooled area under the sROC curve was 0.846 (Fig. 4). The pooled sensitivity was 0.865 (95% CI, 0.821–0.900; I²=94.6%), specificity was 0.702 (95% CI, 0.628–0.766; I²=90.8%), the positive predictive value (PPV) was 0.799 (95% CI, 0.738–0.835; I²=92.7%), and the negative predictive value (NPV) was 0.791 (95% CI, 0.738–0.849; I²=95.6%) (Supplementary Fig. 1 in the online-only Data Supplement). However, substantial heterogeneity (I²≥50%) was noted, likely due to variations in cutoff values (scores of 1, 2, and 3). To explore this heterogeneity further, a subgroup analysis was conducted. Results demonstrated significant differences in sensitivity, specificity, and NPV among the three cutoff values (p<0.05), whereas no significant differences were found for DOR or AUC (p>0.05). The cutoff value of 1 demonstrated the highest sensitivity (0.981) but the lowest specificity (0.178) and PPV (0.560). Conversely, the cutoff value of 3 provided the highest specificity (0.817) but the lowest sensitivity (0.702) and NPV (0.652). The cutoff value of 2 presented balanced diagnostic performance, with sensitivity, specificity, PPV, and NPV each ranging from 0.7 to 0.8.

Diagnostic accuracy of individual items in ID-Migraine

The ID-Migraine tool comprises three items: nausea, photophobia, and disability due to headache. The diagnostic accuracy of each individual item was analyzed to determine its relative contribution to the overall performance of the tool. The analysis revealed significant differences in specificity among the three items (p<0.05). The disability item exhibited the highest sensitivity (0.876) but the lowest specificity (0.537). In contrast, the nausea and photophobia items showed similar diagnostic performance in terms of sensitivity, specificity, PPV, and NPV.

DISCUSSION

The DOR of the ID-Migraine tool was 13.84, and the AUC was 0.846, indicating excellent diagnostic accuracy. Although specificity was relatively moderate at 70.2%, the tool demonstrated robust sensitivity at 86.5%, making it suitable as an initial screening instrument. While ID-Migraine analyses typically use a cutoff value of 2, several studies have examined diagnostic performance (sensitivity and specificity) across different cutoff values. These findings were integrated into our analysis, which confirmed that a cutoff of 2 provides significant diagnostic utility. Comparison with a cutoff value of 3 revealed no substantial differences; however, the NPV at this cutoff was relatively low at 0.65, suggesting that approximately 35% of patients classified as ID-Migraine-negative might be incorrectly identified as non-migraine cases. Given this limitation, a cutoff value of 2 is recommended. Further analysis evaluated the diagnostic contribution of each individual symptom within the three-item questionnaire to determine if any single symptom offered greater diagnostic utility. Among these symptoms, “disability” demonstrated a sensitivity of approximately 80%, specificity of around 50%, and both PPV and NPV of approximately 70%. These findings suggest that “disability” might provide greater overall diagnostic value compared to the other symptoms.

The term “sinus headache” is frequently employed, yet it remains a widely misunderstood clinical complaint, leading many patients to seek evaluation by otolaryngologists [43]. Sinus headache is traditionally associated with sinonasal inflammatory disease. However, a significant proportion of individuals who self-diagnose, or who are diagnosed by physicians as having sinus headaches, are ultimately identified as migraine sufferers. For example, a case series involving 2,991 patients who reported sinus headaches revealed that 88% fulfilled the International Headache Society (IHS) criteria for migraines [44]. Additionally, 42% of those later diagnosed with migraines based on IHS criteria were initially misdiagnosed with sinus headaches. Diagnostic challenges are compounded further by frequent symptom overlap between sinusitis and migraines [44]. A study demonstrated that among patients meeting IHS criteria for migraines, 84% reported sinus pressure, 82% had pain localized in sinus areas, 63% presented nasal congestion, and 40% experienced rhinorrhea during their initial evaluation [44]. Moreover, even when radiographic evidence of chronic rhinosinusitis was present, no significant relationship was observed between pain scores and findings obtained through Lund-Kennedy endoscopy or Lund-Mackay computed tomography (CT) scoring systems [45].

Current differential diagnostic protocols advocate for the use of CT as a primary screening tool [1,2]. Utilizing CT as an initial diagnostic instrument could facilitate rapid differential diagnosis, reduce unnecessary antibiotic prescriptions, and enable timely specialist referrals when necessary [2]. However, CT imaging involves potential unnecessary radiation exposure and imposes considerable cost burdens. Additionally, CT might not be feasible as a screening method in all primary care environments.

In situations where headaches are determined not to originate from sinus-related causes through patient history and physical examination, collaboration with other medical specialties is typically required. This study demonstrates that the ID-Migraine tool provides a simple yet effective method for distinguishing sinus headaches from migraines. Given the high prevalence of migraines, if a migraine is suspected using the ID-Migraine tool, empiric treatment with triptans can be initiated as initial therapy [46,47], along with a neurologist referral. This approach allows timely patient feedback regarding treatment efficacy during neurological consultation, thus minimizing delays in obtaining an accurate diagnosis and initiating appropriate care. Furthermore, if migraine is excluded based on patient history assessments, further investigations can be pursued to determine the actual underlying cause of sinus headaches.

This meta-analysis successfully confirms the utility of ID-Migraine as a screening instrument; however, it is subject to several limitations. First, the 30 included studies were conducted across four continents, representing diverse geographic settings and varying study qualities. This variability likely contributed to the substantial heterogeneity observed among the included studies, potentially influencing pooled estimates of sensitivity, specificity, and DOR. Nevertheless, this diversity might have mitigated selection bias by preventing overrepresentation of studies from a limited number of countries. Second, only English-language publications were included, potentially introducing language bias. However, Deeks’ funnel plot asymmetry test indicated no significant evidence of publication bias, suggesting the meta-analysis likely yielded an accurate estimate of the diagnostic tool’s performance. Third, given the relatively low incidence of migraines, the NPV might have been overestimated due to the high proportion of test-negative cases. Consequently, although the NPV (FN/TN) appeared high, the specificity (70.2%) was lower than the sensitivity (86.5%) [48].

In conclusion, the ID-Migraine screening tool demonstrates high diagnostic accuracy and user-friendliness for identifying migraines in patients presenting with sinus headaches. Implementing this tool can prevent unnecessary tests or treatments and facilitate prompt referrals to appropriate specialists.

Supplementary Materials

The online-only Data Supplement is available with this article at https://doi.org/10.18787/jr.2025.00019.

Supplementary Fig. 1.

Forest plots of sensitivities (A), specificities (B), negative predictive values (C) and positive predictive values (D). CI, confidence interval.

jr-2025-00019-Supplementary-Fig-1.pdf

Supplementary Table 1.

Search strategies and query terms

jr-2025-00019-Supplementary-Table-1.pdf

Supplementary Table 2.

Assessment of methodological quality and risk of bias

jr-2025-00019-Supplementary-Table-2.pdf

Notes

Ethics Statement

Not applicable

Availability of Data and Material

The datasets generated or analyzed during the study are available from the corresponding author on reasonable request.

Conflicts of Interest

Do Hyun Kim and Se Hwan Hwang who are on the editorial board of the Journal of Rhinology were not involved in the editorial evaluation or decision to publish this article. The remaining author has declared no conflicts of interest.

Author Contributions

Conceptualization: Se Hwan Hwang. Data curation: Do Hyun Kim, David W. Jang. Formal analysis: Se Hwan Hwang. Funding acquisition: Do Hyun Kim, Se Hwan Hwang. Investigation: Do Hyun Kim. Methodology: David W. Jang, Se Hwan Hwang. Project administration: Se Hwan Hwang. Resources: David W. Jang. Software: Se Hwan Hwang. Supervision: Se Hwan Hwang. Validation: Do Hyun Kim, David W. Jang. Visualization: Do Hyun Kim, Se Hwan Hwang. Writing—original draft: Do Hyun Kim. Writing—review & editing: David W. Jang, Se Hwan Hwang.

Funding Statement

This work was supported by a National Research Foundation of Korea (NRF) grant funded by the Korean government (MSIT)(RS-2023-00209494), and a Korean Fund for Regenerative Medicine (KFRM) grant funded by the Korean government (23C0121L1).

Acknowledgments

None

Fig. 1

Flowchart depicting the study selection process.

Fig. 2

Deeks’ funnel plot illustrating publication bias.

Fig. 3

Diagnostic accuracy assessment of the included studies. OR, odds ratio; CI, confidence interval.

Fig. 4

Summary receiver operating characteristic (sROC) curve. The thick curve represents the sROC, the thin circular line denotes the 95% confidence region, and the small circle indicates the summary estimate.

Table 1

Summary of study characteristics

Study (year)	Number of participants	Age (yr) (mean, range, or standard deviation)	Sex (male/female)	Nation	Study setting	Study type	ID-Migraine cutoff value used in the analysis	Individual outcome (nausea, photophobia, disability) analysis
Lipton et al. 2003 [5]	443	39.30±10.10	333/110	USA	Primary care practice sites	Multicenter cohort study	2	X
Kim et al. 2006 [13]	176	30.70±9.30	33/143	Korea	Temporomandibular joint and or facial clinic	Prospective cohort study	2	O
Karli et al. 2007 [15]	1,816	45.20±17.00	1,142/674	Turkey	Neurology outpatients	Nationwide, multi-center (41 tertiary care sites) observational study	2	X
Brighina et al. 2005 [12]	222	38.68±12.02	NA	Italy	Headache center	Multicenter cohort study	2	O
Di Piero et al. 2007 [14]	195	40.50±15.80	NA	Italy	Primary care	Multicenter cohort study	2	X
Siva et al. 2008 [18]	227	31.90±5.90	149/78	Turkey	Workplace	Cohort study	2	X
Zarifoglu et al. 2008 [20]	1,014	14.67±1.74	NA	Turkey	Middle school	Cross-sectional study	2	O
Wang et al. 2008 [19]	755	37.00±15.00	NA	China	Neurology outpatients	Cross-sectional study	NA	O
Khu et al. 2008 [16]	584	37.00±11.00	NA	Singapore	Primary care	Cohort study	2	X
Maizels et al. 2008 [17]	68	NA	NA	USA	Primary care	Multicenter cohort study	2	X
Ertas et al. 2009 [22]	1,021	46.5	NA	Turkey	Neurology, ophthalmology, ENT outpatients	Multicenter (11 sites) observational study	2	X
Di Paolo et al. 2009 [21]	37	34.00±11.00	NA	Italy	Dental clinic	Case series	2	X
Mostardini et al. 2009 [23]	230	37.00±15.00	NA	Italy	Emergence department outpatients	Cross-sectional study	2 and 3	X
Gil-Gouveia et al. 2010 [24]	131	38.20±13.20	110/21	Portugal	Headache outpatients	Cross-sectional study	2	O
Gil-Gouveia et al. 2011 [39]	348	47.7	187/161	Portugal	Portuguese clinicians	Prospective observational study	2	X
Mehuys et al. 2012 [26]	629	46.3	NA	Belgium	Community pharmacies	Observational study	2	X
Jurno et al. 2012 [25]	320	38.3	NA	Brazil	Outpatient clinic	Cross-sectional study	2	X
Jin et al. 2013 [27]	466	11.7	NA	China	Junior schools (children and adolescents)	Cross-sectional study	2	X
Streel et al. 2015 [28]	67	20–69	39/28	Belgium	Primary care	Cross-sectional study	2	X
Wang et al. 2015 [29]	1,110	22.03±1.53	796/314	China	Medical university	Cross-sectional study	2	X
Wang et al. 2016 [30]	94	50.16±13.97	NA	China	Community-based, cross-sectional study	Cross-sectional study	2	X
Csépány et al. 2018 [32]	380	36	304/76	Hungary	Two Neurology outpatients (Headache Service)	Cross-sectional study	1, 2, and 3	O
Mattos et al. 2017 [31]	232	40.9±11.2	190/42	Brasil	Headache outpatient clinic	Cross-sectional study	2	O
Grandi et al. 2019 [33]	87	28.3±5.2	87/0	Italy	Gynecological clinics to outpatients	Cohort study	2	X
Oparah et al. 2020 [34]	51	25±4.7	26/25	Nigeria	Medical university	Cross-sectional study	2	X
Thiele et al. 2020 [40]	105	46.5±17.2	80/25	Germany	Headache outpatient clinic	Cross-sectional study	2 and 3	X
Matsushita et al. 2021 [35]	67	61.9±16.8	NA	Japan	Headache clinic	Cross-sectional study	2	O
Rodríguez-Rivas et al. 2023 [36]	117	41.3 (15.3)	95/22	Mexico	Headache clinic	Prospective cohort study	1, 2, and 3	X
Sahu et al. 2023 [37] (Hindi and Punjabi version)	160	39±14	113/47	India	Neurology outpatient clinic	Cross-sectional study	1, 2, and 3	O
Frattale et al. 2024 [38]	94	11.6 (11.3±03.1, 6–17)	58/36	Denmark	Children’s hospital (children and adolescents)	Cross-sectional study	2	O

REFERENCES

1) Jayawardena ADL, Chandra R. Headaches and facial pain in rhinology. Am J Rhinol Allergy 2018;32(1):12–5.

2) Kim R, Patel ZM. Sinus headache: differential diagnosis and an evidence-based approach. Otolaryngol Clin North Am 2020;53(5):897–904.

3) Bernichi JV, Rizzo VL, Villa JF, Santos RF, Caparroz FA. Rhinogenic and sinus headache - Literature review. Am J Otolaryngol 2021;42(6):103113.

4) Amiri P, Kazeminasab S, Nejadghaderi SA, Mohammadinasab R, Pourfathi H, Araj-Khodaei M, et al. Migraine: a review on its history, global epidemiology, risk factors, and comorbidities. Front Neurol 2022;12:800605.

5) Lipton RB, Dodick D, Sadovsky R, Kolodner K, Endicott J, Hettiarachchi J, et al. A self-administered screener for migraine in primary care: the ID Migraine validation study. Neurology 2003;61(3):375–82.

6) Sadovsky R, Dodick DW. Identifying migraine in primary care settings. Am J Med 2005;118:Suppl 1. 11S–7S.

7) Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ 2021;372:n71.

8) Headache Classification Subcommittee of the International Headache Society. The International Classification of Headache Disorders: 2nd edition. Cephalalgia 2004;24:Suppl 1. 9–160.

9) Headache Classification Committee of the International Headache Society (IHS). The International Classification of Headache Disorders, 3rd edition (beta version). Cephalalgia 2013;33(9):629–808.

10) Kim DH, Hwang SH. A review of the long-term efficacy of submucosal medpor implantation for empty nose syndrome: a short communication. J Rhinol 2024;31(3):176–8.

11) Kim DH, Jang DW, Hwang SH. Dose-related effects and bleeding risk of ketorolac in pediatric tonsillectomy. Otolaryngol Head Neck Surg 2025;172(3):821–32.

12) Brighina F, Salemi G, Fierro B, Gasparro A, Balletta G, Aloisio A, et al. A validation study of an Italian version of the ID Migraine: preliminary results. J Headache Pain 2005;6(4):216–9.

13) Kim ST, Kim CY. Use of the ID Migraine questionnaire for migraine in TMJ and Orofacial Pain Clinic. Headache 2006;46(2):253–8.

14) Di Piero V, Altieri M, Conserva G, Petolicchio B, Di Clemente L, Hettiarachchi J, et al. The effects of a sensitisation campaign on unrecognised migraine: the Casilino study. J Headache Pain 2007;8(4):205–8.

15) Karli N, Ertas M, Baykan B, Uzunkaya O, Saip S, Zarifoglu M, et al. The validation of ID Migraine screener in neurology outpatient clinics in Turkey. J Headache Pain 2007;8(4):217–23.

16) Khu JV, Siow HC, Ho KH. Headache diagnosis, management and morbidity in the Singapore primary care setting: findings from a general practice survey. Singapore Med J 2008;49(10):774–9.

17) Maizels M, Houle T. Results of screening with the brief headache screen compared with a modified IDMigraine. Headache 2008;48(3):385–94.

18) Siva A, Zarifoglu M, Ertas M, Saip S, Karli HN, Baykan B, et al. Validity of the ID-Migraine screener in the workplace. Neurology 2008;70(16):1337–45.

19) Wang SJ, Fuh JL, Huang SY, Yang SS, Wu ZA, Hsu CH, et al. Diagnosis and development of screening items for migraine in neurological practice in Taiwan. J Formos Med Assoc 2008;107(6):485–94.

20) Zarifoğlu M, Karli N, Taşkapilioğlu O. Can ID Migraine be used as a screening test for adolescent migraine? Cephalalgia 2008;28(1):65–71.

21) Di Paolo C, Di Nunno A, Vanacore N, Bruti G. ID migraine questionnaire in temporomandibular disorders with craniofacial pain: a study by using a multidisciplinary approach. Neurol Sci 2009;30(4):295–9.

22) Ertaş M, Baykan B, Tuncel D, Gökçe M, Gökçay F, Sirin H, et al. A comparative ID migraine screener study in ophthalmology, ENT and neurology out-patient clinics. Cephalalgia 2009;29(1):68–75.

23) Mostardini C, d’Agostino VC, Dugoni DE, Cerbo R. A possible role of ID-Migraine in the emergency department: study of an emergency department out-patient population. Cephalalgia 2009;29(12):1326–30.

24) Gil-Gouveia R, Martins I. Validation of the Portuguese version of ID-Migraine. Headache 2010;50(3):396–402.

25) Jurno M, Filho PM, Ferreira A, Mattos AC, Souza J, Rezende D. Utility of ID-Migraine as a screening tool in the specialty care (P04.253). Neurology 2012;78(1_supplement):P04.253.

26) Mehuys E, Paemeleire K, Van Hees T, Christiaens T, Van Bortel LM, Van Tongelen I, et al. Self-medication of regular headache: a community pharmacy-based survey. Eur J Neurol 2012;19(8):1093–9.

27) Jin Z, Shi L, Wang YJ, Yang LG, Shi YH, Shen LW, et al. Prevalence of headache among children and adolescents in Shanghai, China. J Clin Neurosci 2013;20(1):117–21.

28) Streel S, Donneau AF, Dardenne N, Hoge A, Bruyère O, Albert A, et al. Validation of an extended French version of ID Migraine^™ as a migraine-screening tool. Cephalalgia 2015;35(5):437–42.

29) Wang X, San YZ, Sun JM, Zhou HB, Li X, Zhang ZM, et al. Validation of the Chinese version of ID-Migraine in medical students and systematic review with meta-analysis concerning its diagnostic accuracy. J Oral Facial Pain Headache 2015;29(3):265–78.

30) Wang X, Xing Y, Sun J, Zhou H, Yu H, Zhao Y, et al. Prevalence, associated factors, and impact on quality of life of migraine in a community in Northeast China. J Oral Facial Pain Headache 2016;30(2):139–49.

31) Mattos ACMT, Souza JA, Moreira Filho PF, Jurno ME, Velarde LGC. ID-Migraine^™ questionnaire and accurate diagnosis of migraine. Arq Neuro-Psiquiatr 2017;75(7):446–50.

32) Csépány É, Tóth M, Gyüre T, Magyar M, Bozsik G, Bereczki D, et al. The validation of the Hungarian version of the ID-migraine questionnaire. J Headache Pain 2018;19(1):106.

33) Grandi G, Imbrogno MG, Cainazzo MM, Pini LA, Baraldi C, Guerzoni S, et al. Easy tools to screen Italian women suffering from migraine with and without aura in early reproductive age. Eur J Obstet Gynecol Reprod Biol 2019;242:63–7.

34) Oparah SK, Asibong UE, Olose EO, Ozomma SI. Utility of the ID-migraine tool in migraine without aura diagnosis: an experience from Nigeria. J Med Allied Sci 2020;10(2):91–7.

35) Matsushita M, Matsumoto K, Kitamura S, Komatsu N, Seo H, Takeuchi S. Validation of the “My Headache Checker” that includes osmophobia in the diagnosis of migraine. J Gen Fam Med 2021;22(1):24–7.

36) Rodríguez-Rivas R, Moreno-Martínez CA, Cerqueira TL, Enríquez-Peregrino KG, Martínez-Piña DA, Vargas-Rodríguez JN, et al. Translation, cross-cultural adaptation, and validation of a Latin American Spanish version of the ID Migraine screening test. Headache 2023;63(7):872–9.

37) Sahu P, Chaturvedi P, Khan R, Singla M, Munshi A, Singh G. Translation and validation of ID-Migraine questionnaire to North-Indian vernacular languages. Ann Indian Acad Neurol 2023;26(4):543–8.

38) Frattale I, Papetti L, Ursitti F, Sforza G, Monte G, Mazzone L, et al. ID-Migraine test for pediatric population: preliminary results from the Italian validation. Confin Cephalalgica 2024;31(Suppl 1):15761.

39) Gil-Gouveia R. Evaluating the performance of ID-migraine, MS-Q and MIDAS scales in Portuguese clinicians [abstract]. Cephalalgia 2011;31(Suppl 1):145–6.

40) Thiele A, Strauß S, Angermaier A, Kronenbuerger M, Fleischmann R. Translation and validation of an extended German version of ID Migraine^™ as a migraine screening tool. Cephalalgia Rep 2020;3:2515816320962773.

41) Hoeboer SH, van der Geest PJ, Nieboer D, Groeneveld AB. The diagnostic accuracy of procalcitonin for bacteraemia: a systematic review and meta-analysis. Clin Microbiol Infect 2015;21(5):474–81.

42) Whiting PF, Rutjes AW, Westwood ME, Mallett S, Deeks JJ, Reitsma JB, et al. QUADAS-2: a revised tool for the quality assessment of diagnostic accuracy studies. Ann Intern Med 2011;155(8):529–36.

43) Patel ZM, Setzen M, Poetker DM, DelGaudio JM. Evaluation and management of “sinus headache” in the otolaryngology practice. Otolaryngol Clin North Am 2014;47(2):269–87.

44) Schreiber CP, Hutchinson S, Webster CJ, Ames M, Richardson MS, Powers C. Prevalence of migraine in patients with a history of self-reported or physician-diagnosed “sinus” headache. Arch Intern Med 2004;164(16):1769–72.

45) Cox DR, Ashby S, DeConde AS, Mace JC, Orlandi RR, Smith TL, et al. Dyad of pain and depression in chronic rhinosinusitis. Int Forum Allergy Rhinol 2016;6(3):308–14.

46) Patel ZM, Kennedy DW, Setzen M, Poetker DM, DelGaudio JM. “Sinus headache”: rhinogenic headache or migraine? An evidence-based guide to diagnosis and treatment”. Int Forum Allergy Rhinol 2013;3(3):221–30.

47) Hu S, Helman S, Filip P, Cabin J, Colley P. The role of the otolaryngologist in the evaluation and management of headaches. Am J Otolaryngol 2019;40(1):115–20.

48) Kim DH, Kim GJ, Kim SW, Hwang SH. Predictive value of ipsilateral central lymph node metastasis for contralateral central lymph node metastasis in patients with thyroid cancer: systematic review and meta-analysis. Head Neck 2021;43(10):3177–84.